DNDN: Nice. Could be a retrace to 11 short term but there's also that big gap below that makes it attractive for Puts now.
The only thing that usually scares me about these bio-pharma stocks is that they often have some patents and buyouts coming from out of nowhere which makes the chart T/A obsolete.